Home » Outlook Reports Bevacizumab Trial Delays
Outlook Reports Bevacizumab Trial Delays
Outlook Therapeutics reported enrollment delays for a clinical trial of Lytenava (bevacizumab-vikg), its investigational formulation of bevacizumab for use in retinal treatments.
The NORSE 2 trial is continuing to screen and treat patients but is subject to additional COVID-19 safety protocols that have caused some sites to temporarily shut down and enrollment to slow.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May